NPY2
Boehringer Ingelheim Discontinues NPY2 Obesity Drug Development with Gubra, Focuses on Triple-Agonist Candidate
Boehringer Ingelheim, Gubra, obesity drug, NPY2, triple-agonist, BI 3034701, clinical trials
Actionable Insights Powered by AI
Boehringer Ingelheim, Gubra, obesity drug, NPY2, triple-agonist, BI 3034701, clinical trials